Spots Global Cancer Trial Database for clovis oncology
Every month we try and update this database with for clovis oncology cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | NCT02042378 | Pancreatic Canc... Pancreatic Duct... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | NCT03954366 | Neoplasms | Rucaparib Rosuvastatin Oral Contracept... | 18 Years - | pharmaand GmbH | |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | NCT01968213 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Rucaparib Placebo | 18 Years - | pharmaand GmbH | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib | NCT02986100 | Solid Tumor | C-14 labeled Ru... Rucaparib | 18 Years - | pharmaand GmbH | |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | NCT03954366 | Neoplasms | Rucaparib Rosuvastatin Oral Contracept... | 18 Years - | pharmaand GmbH | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Pharmacokinetic Drug-Drug Interaction Study of Rucaparib | NCT02740712 | Neoplasms | Caffeine Warfarin Omeprazole Midazolam digoxin Vitamin K Rucaparib | 18 Years - | pharmaand GmbH | |
| Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor | NCT03521037 | Neoplasms | Rucaparib camsy... | 18 Years - | pharmaand GmbH | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
